Search results
Results from the Tech24 Deals Content Network
Health Canada received a submission from Moderna on June 29, 2023 for yet another reformulated COVID-19 vaccine based on the Omicron XBB.1.5 subvariant of SARS-CoV-2. [131] The updated version was tested in a small human trial of 101 participants who had previously received four doses of previous formulations of the Moderna COVID-19 vaccine.
Users of this vaccine passport, the first in Canada, faced fewer COVID-19 public health restrictions. [2] By early July, the demand for the paper vaccine passports temporarily overwhelmed the system. At the same time, the province reached a new "marker in the pandemic"—the COVID-19 vaccines supply exceeded "demand on a daily basis." [2] [44]
The COVID-19 vaccination campaign in Quebec (French: Campagne de vaccination contre la Covid-19 au Québec) was a provincial effort to distribute and administer vaccines against COVID-19. Quebec received their first shipments of COVID-19 vaccines on December 13, 2020. [2] Priority vaccination of long-term care home residents and healthcare ...
COVID-19 vaccination in Ontario. COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer-BioNTech COVID-19 vaccine were administered. [1] In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. [2]
The CDC has recommended updated Covid booster shots from Pfizer and Moderna. The shots target the original virus and omicron subvariants BA.4 and BA.5.
A COVID-19 vaccine card is a record often given to those who have received a COVID-19 vaccine showing information such as the date (s) one has received the shot (s) and the brand of vaccine one has received, sometimes including the lot number. The card also contains information identifying the recipient and the location where the shot was given ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. [31] It contains a recombinant spike protein from the SARS-CoV-2 Omicron variant lineage JN.1.